{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T13:05:21Z","timestamp":1784120721347,"version":"3.55.0"},"reference-count":161,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T00:00:00Z","timestamp":1765497600000},"content-version":"am","delay-in-days":314,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.pharmthera.2024.108773","type":"journal-article","created":{"date-parts":[[2024,12,6]],"date-time":"2024-12-06T07:55:32Z","timestamp":1733471732000},"page":"108773","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Glucuronidation of orally administered drugs and the value of nanocarriers in strategies for its overcome"],"prefix":"10.1016","volume":"266","author":[{"given":"Laura","family":"Hervieu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Claire","family":"Groo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00e9my","family":"Bellien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Guerrot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aur\u00e9lie","family":"Malzert-Fr\u00e9on","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.pharmthera.2024.108773_bb0005","doi-asserted-by":"crossref","first-page":"689","DOI":"10.3109\/02652048.2011.590613","article-title":"Gastroretentive microparticles for drug delivery applications","volume":"28","author":"Adebisi","year":"2011","journal-title":"Journal of Microencapsulation"},{"issue":"5","key":"10.1016\/j.pharmthera.2024.108773_bb0010","doi-asserted-by":"crossref","DOI":"10.3390\/jpm12050673","article-title":"The promise of nanotechnology in personalized medicine","volume":"12","author":"Alghamdi","year":"2022","journal-title":"Journal of Personalized Medicine"},{"issue":"8","key":"10.1016\/j.pharmthera.2024.108773_bb0015","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.3390\/pharmaceutics15082073","article-title":"Formulation and evaluation of a self-microemulsifying drug delivery system of raloxifene with improved solubility and oral bioavailability","volume":"15","author":"Ansari","year":"2023","journal-title":"Pharmaceutics"},{"issue":"1","key":"10.1016\/j.pharmthera.2024.108773_bb0020","doi-asserted-by":"crossref","first-page":"102","DOI":"10.2133\/dmpk.DMPK-10-SH-086","article-title":"Evaluation of pharmaceutical excipients as cosolvents in 4-methyl umbelliferone glucuronidation in human liver microsomes: Applications for compounds with low solubility","volume":"26","author":"Argikar","year":"2011","journal-title":"Drug Metabolism and Pharmacokinetics"},{"issue":"9","key":"10.1016\/j.pharmthera.2024.108773_bb0025","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.3109\/00498259109039556","article-title":"Identification of the metabolites of irinotecan, a new derivative of camptothecin, in rat bile and its biliary excretion","volume":"21","author":"Atsumi","year":"1991","journal-title":"Xenobiotica"},{"issue":"8","key":"10.1016\/j.pharmthera.2024.108773_bb0030","doi-asserted-by":"crossref","first-page":"975","DOI":"10.3390\/ph15080975","article-title":"Intestinal absorption study: Challenges and absorption enhancement strategies in improving oral drug delivery","volume":"15","author":"Azman","year":"2022","journal-title":"Pharmaceuticals"},{"issue":"8","key":"10.1016\/j.pharmthera.2024.108773_bb0035","first-page":"903","article-title":"Robust expansion of human hepatocytes in Fah\u2212\/\u2212\/Rag2\u2212\/\u2212\/Il2rg\u2212\/\u2212 mice","volume":"25","author":"Azuma","year":"2007","journal-title":"Nature Biotechnology 2007 25:8"},{"issue":"S1","key":"10.1016\/j.pharmthera.2024.108773_bb0040","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.1002\/jcph.1493","article-title":"Characterization of the ontogeny of hepatic UDP-glucuronosyltransferase enzymes based on glucuronidation activity measured in human liver microsomes","volume":"59","author":"Bad\u00e9e","year":"2019","journal-title":"The Journal of Clinical Pharmacology"},{"issue":"1\u20132","key":"10.1016\/j.pharmthera.2024.108773_bb0045","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s11010-008-0001-5","article-title":"Lipid-activated transcription factors control bile acid glucuronidation","volume":"326","author":"Barbier","year":"2009","journal-title":"Molecular and Cellular Biochemistry"},{"issue":"5","key":"10.1016\/j.pharmthera.2024.108773_bb0050","doi-asserted-by":"crossref","first-page":"509","DOI":"10.2174\/138920007780866834","article-title":"Presystemic metabolism of orally administered peptide drugs and strategies to overcome it","volume":"8","author":"Bernkop-Schnurch","year":"2007","journal-title":"Current Drug Metabolism"},{"issue":"6","key":"10.1016\/j.pharmthera.2024.108773_bb0055","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/0006-2952(83)90610-X","article-title":"UDP-glucuronosyltransferase activities: Guidelines for consistent interim terminology and assay conditions","volume":"32","author":"Bock","year":"1983","journal-title":"Biochemical Pharmacology"},{"issue":"1\u20132","key":"10.1016\/j.pharmthera.2024.108773_bb0060","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/S0168-3659(99)00042-5","article-title":"Optimizing oral absorption of peptides using prodrug strategies","volume":"62","author":"Borchardt","year":"1999","journal-title":"Journal of Controlled Release"},{"issue":"7","key":"10.1016\/j.pharmthera.2024.108773_bb0065","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1016\/j.xphs.2019.02.009","article-title":"In vitro-in vivo extrapolation and hepatic clearance-dependent Underprediction","volume":"108","author":"Bowman","year":"2019","journal-title":"Journal of Pharmaceutical Sciences"},{"issue":"5","key":"10.1016\/j.pharmthera.2024.108773_bb0070","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1124\/dmd.109.030130","article-title":"A humanized UGT1 mouse model expressing the UGT1A1*28 allele for assessing drug clearance by UGT1A1-dependent glucuronidation","volume":"38","author":"Cai","year":"2010","journal-title":"Drug Metabolism and Disposition"},{"issue":"1","key":"10.1016\/j.pharmthera.2024.108773_bb0075","article-title":"The pharmaceutical excipient PEG400 affect the absorption of baicalein in Caco-2 monolayer model by interacting with UDP-glucuronosyltransferases and efflux transport proteins","volume":"10","author":"Cao","year":"2022"},{"issue":"4","key":"10.1016\/j.pharmthera.2024.108773_bb0080","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1021\/mp900065b","article-title":"The role of pH in the glucuronidation of raloxifene, mycophenolic acid and ezetimibe","volume":"6","author":"Chang","year":"2009","journal-title":"Molecular Pharmaceutics"},{"issue":"4","key":"10.1016\/j.pharmthera.2024.108773_bb0085","doi-asserted-by":"crossref","first-page":"524","DOI":"10.34172\/apb.2020.064","article-title":"Lipid drug carriers for Cancer therapeutics: An insight into lymphatic targeting, P-gp, CYP3A4 modulation and bioavailability enhancement","volume":"10","author":"Chaturvedi","year":"2020","journal-title":"Advanced Pharmaceutical Bulletin"},{"issue":"4","key":"10.1016\/j.pharmthera.2024.108773_bb0090","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/ejhg.2011.206","article-title":"UGT1A1 is a major locus influencing bilirubin levels in African Americans","volume":"20","author":"Chen","year":"2011","journal-title":"European Journal of Human Genetics 2012 20:4"},{"issue":"47","key":"10.1016\/j.pharmthera.2024.108773_bb0095","doi-asserted-by":"crossref","first-page":"19143","DOI":"10.1073\/pnas.1319123110","article-title":"Intestinal glucuronidation protects against chemotherapy-induced toxicity by irinotecan (CPT-11)","volume":"110","author":"Chen","year":"2013","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"2","key":"10.1016\/j.pharmthera.2024.108773_bb0100","doi-asserted-by":"crossref","first-page":"204","DOI":"10.2174\/138161210790112674","article-title":"Pharmacogenetics of phase I and phase II drug metabolism","volume":"16","author":"Crettol","year":"2009","journal-title":"Current Pharmaceutical Design"},{"key":"10.1016\/j.pharmthera.2024.108773_bb0105","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/B978-0-12-415813-9.00003-9","article-title":"Metabolism of xenobiotics of human environments","volume":"112","author":"Croom","year":"2012","journal-title":"Progress in Molecular Biology and Translational Science"},{"key":"10.1016\/j.pharmthera.2024.108773_bb0110","first-page":"8443","article-title":"Glucuronidation as a mechanism of intrinsic drug resistance in human colon cancer: Reversal of resistance by food additives","volume":"63","author":"Cummings","year":"2003","journal-title":"Cancer Research"},{"issue":"1","key":"10.1016\/j.pharmthera.2024.108773_bb0115","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.bcp.2003.07.019","article-title":"Glucuronidation as a mechanism of intrinsic drug resistance in colon cancer cells: Contribution of drug transport proteins","volume":"67","author":"Cummings","year":"2004","journal-title":"Biochemical Pharmacology"},{"issue":"1","key":"10.1016\/j.pharmthera.2024.108773_bb0120","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1517\/17425250802568009","article-title":"Computational approaches to predict drug metabolism","volume":"5","author":"Czodrowski","year":"2009","journal-title":"Expert Opinion on Drug Metabolism & Toxicology"},{"key":"10.1016\/j.pharmthera.2024.108773_bb0125","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.jconrel.2016.06.016","article-title":"Nanoparticles for oral delivery: Design, evaluation and state-of-the-art","volume":"240","author":"Date","year":"2016","journal-title":"Journal of Controlled Release"},{"key":"10.1016\/j.pharmthera.2024.108773_bb0130","first-page":"1","article-title":"In silico models of drug metabolism and drug interactions","author":"Dimelow","year":"2012","journal-title":"Encyclopedia of Drug Metabolism and Interactions"},{"issue":"9","key":"10.1016\/j.pharmthera.2024.108773_bb0135","doi-asserted-by":"crossref","first-page":"2864","DOI":"10.1021\/acs.molpharmaceut.6b00851","article-title":"Sodium Oleate-based nanoemulsion enhances oral absorption of chrysin through inhibition of UGT-mediated metabolism","volume":"14","author":"Dong","year":"2017","journal-title":"Molecular Pharmaceutics"},{"issue":"7","key":"10.1016\/j.pharmthera.2024.108773_bb0140","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1021\/bc100154g","article-title":"Novel nanoassemblies composed of squalenoyl-paclitaxel derivatives: Synthesis, characterization, and biological evaluation","volume":"21","author":"Dosio","year":"2010","journal-title":"Bioconjugate Chemistry"},{"issue":"3","key":"10.1016\/j.pharmthera.2024.108773_bb0145","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1124\/dmd.105.008458","article-title":"A combined approach to drug metabolism and toxicity assessment","volume":"34","author":"Ekins","year":"2006","journal-title":"Drug Metabolism and Disposition"},{"key":"10.1016\/j.pharmthera.2024.108773_bb0150","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.jconrel.2021.12.003","article-title":"Smart design approaches for orally administered lipophilic prodrugs to promote lymphatic transport","volume":"341","author":"Elz","year":"2022","journal-title":"Journal of Controlled Release"},{"key":"10.1016\/j.pharmthera.2024.108773_bb0155","series-title":"Advanced drug delivery reviews","first-page":"557","article-title":"Oral drug delivery with polymeric nanoparticles: The gastrointestinal mucus barriers","volume":"64","author":"Ensign","year":"2012"},{"issue":"1","key":"10.1016\/j.pharmthera.2024.108773_bb0160","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ddtec.2005.05.019","article-title":"Nanoparticle uptake by the oral route: Fulfilling its potential?","volume":"2","author":"Florence","year":"2005","journal-title":"Drug Discovery Today: Technologies"},{"issue":"11","key":"10.1016\/j.pharmthera.2024.108773_bb0165","doi-asserted-by":"crossref","first-page":"5024","DOI":"10.1073\/pnas.0913290107","article-title":"Developmental hyperbilirubinemia and CNS toxicity in mice humanized with the UDP glucuronosyltransferase 1 (UGT1) locus","volume":"107","author":"Fujiwara","year":"2010","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"1","key":"10.1016\/j.pharmthera.2024.108773_bb0170","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.dmpk.2017.10.002","article-title":"Species differences in drug glucuronidation: Humanized UDP-glucuronosyltransferase 1 mice and their application for predicting drug glucuronidation and drug-induced toxicity in humans","volume":"33","author":"Fujiwara","year":"2018","journal-title":"Drug Metabolism and Pharmacokinetics"},{"issue":"2","key":"10.1016\/j.pharmthera.2024.108773_bb0175","doi-asserted-by":"crossref","first-page":"171","DOI":"10.2133\/dmpk.DMPK-11-RG-088","article-title":"Quantitative prediction of intestinal glucuronidation of drugs in rats using in vitro metabolic clearance data","volume":"27","author":"Furukawa","year":"2012","journal-title":"Drug Metabolism and Pharmacokinetics"},{"issue":"3","key":"10.1016\/j.pharmthera.2024.108773_bb0180","doi-asserted-by":"crossref","first-page":"205","DOI":"10.3109\/00498254.2013.828362","article-title":"Species differences in intestinal glucuronidation activities between humans, rats, dogs and monkeys","volume":"44","author":"Furukawa","year":"2014","journal-title":"Xenobiotica"},{"issue":"15","key":"10.1016\/j.pharmthera.2024.108773_bb0185","doi-asserted-by":"crossref","first-page":"3220","DOI":"10.3390\/polym14153220","article-title":"A QbD Approach to Design and to Optimize the Self-Emulsifying Resveratrol\u2013Phospholipid Complex to Enhance Drug Bioavailability through Lymphatic Transport","volume":"14","author":"Gausuzzaman","year":"2022","journal-title":"Polymers"},{"issue":"1","key":"10.1016\/j.pharmthera.2024.108773_bb0190","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1177\/0192623313518113","article-title":"Comparative anatomy, physiology, and mechanisms of disease production of the esophagus, stomach, and small intestine","volume":"42","author":"Gelberg","year":"2014","journal-title":"Toxicologic Pathology"},{"issue":"6","key":"10.1016\/j.pharmthera.2024.108773_bb0195","doi-asserted-by":"crossref","first-page":"2659","DOI":"10.1210\/en.2002-0052","article-title":"Human uridine diphosphate-glucuronosyltransferase UGT2B7 conjugates mineralocorticoid and glucocorticoid metabolites","volume":"144","author":"Girard","year":"2003","journal-title":"Endocrinology"},{"key":"10.1016\/j.pharmthera.2024.108773_bb0200","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.ejps.2016.11.025","article-title":"Comparison of 2 strategies to enhance pyridoclax solubility: Nanoemulsion delivery system versus salt synthesis","volume":"97","author":"Groo","year":"2017","journal-title":"European Journal of Pharmaceutical Sciences"},{"key":"10.1016\/j.pharmthera.2024.108773_bb0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2020.119655","article-title":"Pyridoclax-loaded nanoemulsion for enhanced anticancer effect on ovarian cancer","volume":"587","author":"Groo","year":"2020","journal-title":"International Journal of Pharmaceutics"},{"issue":"1\u20132","key":"10.1016\/j.pharmthera.2024.108773_bb0210","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ijpharm.2015.12.010","article-title":"Evaluation of the versatile character of a nanoemulsion formulation","volume":"498","author":"Gu\u00e9","year":"2016","journal-title":"International Journal of Pharmaceutics"},{"key":"10.1016\/j.pharmthera.2024.108773_bb0215","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.jddst.2019.05.014","article-title":"Emerging strategies for enhancing buccal and sublingual administration of nutraceuticals and pharamaceuticals","volume":"52","author":"Guo","year":"2019","journal-title":"Journal of Drug Delivery Science and Technology"},{"key":"10.1016\/j.pharmthera.2024.108773_bb0220","first-page":"1005","article-title":"Nanotherapeutics in the eU: An overview on current state and future directions","volume":"9","author":"Hafner","year":"2014","journal-title":"International Journal of Nanomedicine Dovepress"},{"issue":"9","key":"10.1016\/j.pharmthera.2024.108773_bb0225","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.3390\/ijms18091983","article-title":"In vitro glucuronidation of wushanicaritin by liver microsomes, intestine microsomes and expressed human UDP-glucuronosyltransferase enzymes","volume":"18","author":"Hong","year":"2017","journal-title":"International Journal of Molecular Sciences"},{"issue":"8","key":"10.1016\/j.pharmthera.2024.108773_bb0230","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1124\/dmd.120.090696","article-title":"Human liver Microsomes immobilized on Magnetizable beads: A novel approach to study in vitro drug metabolism","volume":"48","author":"Horspool","year":"2020","journal-title":"Drug Metabolism and Disposition"},{"issue":"1","key":"10.1016\/j.pharmthera.2024.108773_bb0235","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13321-022-00626-3","article-title":"In silico prediction of UGT-mediated metabolism in drug-like molecules via graph neural network","volume":"14","author":"Huang","year":"2022","journal-title":"Journal of Cheminformatics"},{"issue":"1","key":"10.1016\/j.pharmthera.2024.108773_bb0240","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.maturitas.2012.05.014","article-title":"Polymeric particulate technologies for oral drug delivery and targeting: A pathophysiological perspective","volume":"73","author":"Hunter","year":"2012","journal-title":"Maturitas"},{"issue":"3","key":"10.1016\/j.pharmthera.2024.108773_bb0245","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1124\/pr.110.003459","article-title":"Prodrugs\u2014from serendipity to rational design","volume":"63","author":"Huttunen","year":"2011","journal-title":"Pharmacological Reviews"},{"issue":"15","key":"10.1016\/j.pharmthera.2024.108773_bb0250","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1200\/JCO.2005.05.2464","article-title":"Irinogenetics: What is the right star?","volume":"24","author":"Innocenti","year":"2006","journal-title":"Journal of Clinical Oncology"},{"issue":"6","key":"10.1016\/j.pharmthera.2024.108773_bb0255","doi-asserted-by":"crossref","DOI":"10.2174\/1389200218666170316093301","article-title":"Drug metabolism in preclinical drug development: A survey of the discovery process, toxicology, and computational tools","volume":"18","author":"Issa","year":"2017","journal-title":"Current Drug Metabolism"},{"issue":"1","key":"10.1016\/j.pharmthera.2024.108773_bb0260","first-page":"43","article-title":"UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity","volume":"2","author":"Iyer","year":"2002","journal-title":"The Pharmacogenomics Journal 2002 2:1"},{"issue":"4","key":"10.1016\/j.pharmthera.2024.108773_bb0265","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1021\/acs.molpharmaceut.7b01090","article-title":"The effect of Piperine pro-Nano Lipospheres on direct intestinal phase II metabolism: The Raloxifene paradigm of enhanced Oral bioavailability","volume":"15","author":"Izgelov","year":"2018","journal-title":"Molecular Pharmaceutics"},{"issue":"3","key":"10.1016\/j.pharmthera.2024.108773_bb0270","doi-asserted-by":"crossref","first-page":"45","DOI":"10.18433\/J33S3Z","article-title":"Effects of monoglycerides on rhodamine 123 accumulation, estradiol 17 beta-D-glucuronide bidirectional transport and MRP2 protein expression within Caco-2 cells","volume":"11","author":"Jia","year":"2008","journal-title":"Journal of Pharmacy & Pharmaceutical Sciences\u00a0: A Publication of the Canadian Society for Pharmaceutical Sciences, Societe Canadienne Des Sciences Pharmaceutiques"},{"issue":"2","key":"10.1016\/j.pharmthera.2024.108773_bb0275","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1006\/abbi.1997.9949","article-title":"The Regio- and stereo-selectivity of C19 and C21 Hydroxysteroid Glucuronidation by UGT2B7 and UGT2B11","volume":"341","author":"Jin","year":"1997","journal-title":"Archives of Biochemistry and Biophysics"},{"issue":"8","key":"10.1016\/j.pharmthera.2024.108773_bb0280","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1002\/mnfr.201100117","article-title":"Enhancing the bioavailability of resveratrol by combining it with piperine","volume":"55","author":"Johnson","year":"2011","journal-title":"Molecular Nutrition and Food Research"},{"issue":"8\u20139","key":"10.1016\/j.pharmthera.2024.108773_bb0285","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1080\/00498254.2023.2280785","article-title":"Empirical scaling factor for predicting human pharmacokinetic profiles of disproportionate metabolites using the Css\u2013MRTpo method and chimeric mice with humanised livers","volume":"53","author":"Kamimura","year":"2023","journal-title":"Xenobiotica"},{"issue":"5","key":"10.1016\/j.pharmthera.2024.108773_bb0290","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1002\/bdd.2510160502","article-title":"Comparison of the gastrointestinal anatomy, physiology, and biochemistry of humans and commonly used laboratory animals","volume":"16","author":"Kararli","year":"1995","journal-title":"Biopharmaceutics & Drug Disposition"},{"key":"10.1016\/j.pharmthera.2024.108773_bb0295","doi-asserted-by":"crossref","DOI":"10.1016\/j.tiv.2022.105533","article-title":"Novel insights into bile acid detoxification via CYP, UGT and SULT enzymes","volume":"87","author":"Kastrinou Lampou","year":"2023","journal-title":"Toxicology In Vitro"},{"issue":"1","key":"10.1016\/j.pharmthera.2024.108773_bb0300","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1124\/dmd.107.018184","article-title":"Hepatic UDP-glucuronosyltransferases responsible for Glucuronidation of thyroxine in humans","volume":"36","author":"Kato","year":"2008","journal-title":"Drug Metabolism and Disposition"},{"issue":"8","key":"10.1016\/j.pharmthera.2024.108773_bb0305","doi-asserted-by":"crossref","first-page":"3072","DOI":"10.1073\/pnas.1808255116","article-title":"Humanized UGT2 and CYP3A transchromosomic rats for improved prediction of human drug metabolism","volume":"116","author":"Kazuki","year":"2019","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"6","key":"10.1016\/j.pharmthera.2024.108773_bb0310","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1124\/dmd.30.6.694","article-title":"Characterization of Raloxifene Glucuronidation in vitro: Contribution of intestinal metabolism to Presystemic clearance","volume":"30","author":"Kemp","year":"2002","journal-title":"Drug Metabolism and Disposition"},{"issue":"4","key":"10.1016\/j.pharmthera.2024.108773_bb0315","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S2221-1691(13)60060-X","article-title":"Bioavailability enhancers of herbal origin: An overview","volume":"3","author":"Kesarwani","year":"2013","journal-title":"Asian Pacific Journal of Tropical Biomedicine"},{"key":"10.1016\/j.pharmthera.2024.108773_bb0320","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2020.105677","article-title":"Drug glucuronidation assays on human liver microsomes immobilized on microfluidic flow-through reactors","volume":"158","author":"Kiiski","year":"2021","journal-title":"European Journal of Pharmaceutical Sciences"},{"issue":"1\u20132","key":"10.1016\/j.pharmthera.2024.108773_bb0325","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ijpharm.2008.09.049","article-title":"Metabolic inhibition and kinetics of raloxifene by pharmaceutical excipients in human liver microsomes","volume":"368","author":"Kim","year":"2009","journal-title":"International Journal of Pharmaceutics"},{"issue":"3","key":"10.1016\/j.pharmthera.2024.108773_bb0330","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1007\/s11095-014-1511-3","article-title":"Combining structure- and ligand-based approaches to improve site of metabolism prediction in CYP2C9 substrates","volume":"32","author":"Kingsley","year":"2015","journal-title":"Pharmaceutical Research"},{"issue":"4","key":"10.1016\/j.pharmthera.2024.108773_bb0335","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1111\/bcp.12086","article-title":"Renal drug metabolism in humans: The potential for drug\u2013endobiotic interactions involving cytochrome P450 (CYP) and UDP-glucuronosyltransferase (UGT)","volume":"76","author":"Knights","year":"2013","journal-title":"British Journal of Clinical Pharmacology"},{"issue":"3","key":"10.1016\/j.pharmthera.2024.108773_bb0340","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1111\/j.1365-2125.2009.03469.x","article-title":"Aldosterone glucuronidation by human liver and kidney microsomes and recombinant UDP-glucuronosyltransferases: Inhibition by NSAIDs","volume":"68","author":"Knights","year":"2009","journal-title":"British Journal of Clinical Pharmacology"},{"issue":"6","key":"10.1016\/j.pharmthera.2024.108773_bb0345","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.1030","article-title":"Analysis of in vitro and in vivo metabolism of zidovudine and gemfibrozil in trans-chromosomic mouse line expressing human UGT2 enzymes","volume":"10","author":"Kobayashi","year":"2022","journal-title":"Pharmacology Research & Perspectives"},{"key":"10.1016\/j.pharmthera.2024.108773_bb0350","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2019.08.018","article-title":"Inhibition of human UDP-glucuronosyltransferase (UGT) enzymes by kinase inhibitors: Effects of dabrafenib, ibrutinib, nintedanib, trametinib and BIBF 1202","volume":"169","author":"Korprasertthaworn","year":"2019","journal-title":"Biochemical Pharmacology"},{"issue":"1","key":"10.1016\/j.pharmthera.2024.108773_bb0355","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1002\/prp2.2","article-title":"Glucuronidation of drugs in humanized UDP-glucuronosyltransferase 1 mice: Similarity with glucuronidation in human liver microsomes","volume":"1","author":"Kutsuno","year":"2013","journal-title":"Pharmacology Research & Perspectives"},{"issue":"Suppl. 1","key":"10.1016\/j.pharmthera.2024.108773_bb0360","doi-asserted-by":"crossref","first-page":"S55","DOI":"10.1016\/0006-2952(91)90392-I","article-title":"Influence of morphine concentration on detergent activation of rat liver morphine-UDP-glucuronosyltransferase","volume":"42","author":"Lear","year":"1991","journal-title":"Biochemical Pharmacology"},{"issue":"3","key":"10.1016\/j.pharmthera.2024.108773_bb0365","doi-asserted-by":"crossref","first-page":"136","DOI":"10.12793\/tcp.2022.30.e13","volume":"30","author":"Lee","year":"2022","journal-title":"Translational and Clinical Pharmacology"},{"issue":"10","key":"10.1016\/j.pharmthera.2024.108773_bb0370","doi-asserted-by":"crossref","first-page":"5222","DOI":"10.1210\/jc.2004-0331","article-title":"Specificity and Regioselectivity of the conjugation of estradiol, Estrone, and their Catecholestrogen and Methoxyestrogen metabolites by human uridine Diphospho-glucuronosyltransferases expressed in endometrium","volume":"89","author":"L\u00e9pine","year":"2004","journal-title":"The Journal of Clinical Endocrinology & Metabolism"},{"key":"10.1016\/j.pharmthera.2024.108773_bb0375","doi-asserted-by":"crossref","first-page":"33","DOI":"10.4267\/10608\/1785","article-title":"R\u00f4le des UDP-glucuronosyltransf\u00e9rases (UGT) dans le m\u00e9tabolisme des hormones st\u00e9ro\u00efdiennes","volume":"17","author":"L\u00e9vesque","year":"2001","journal-title":"M\u00e9decine\/Sciences"},{"issue":"13","key":"10.1016\/j.pharmthera.2024.108773_bb0380","doi-asserted-by":"crossref","first-page":"3869","DOI":"10.1021\/bi002607y","article-title":"Isolation and characterization of the UGT2B28 cDNA encoding a novel human steroid conjugating UDP-glucuronosyltransferase","volume":"40","author":"L\u00e9vesque","year":"2001","journal-title":"Biochemistry"},{"issue":"1\u20132","key":"10.1016\/j.pharmthera.2024.108773_bb0385","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijpharm.2007.05.049","article-title":"Developing early formulations: Practice and perspective","volume":"341","author":"Li","year":"2007","journal-title":"International Journal of Pharmaceutics"},{"issue":"3","key":"10.1016\/j.pharmthera.2024.108773_bb0390","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1208\/s12248-010-9200-6","article-title":"Species and gender differences affect the metabolism of emodin via glucuronidation","volume":"12","author":"Liu","year":"2010","journal-title":"AAPS Journal"},{"issue":"3","key":"10.1016\/j.pharmthera.2024.108773_bb0395","doi-asserted-by":"crossref","first-page":"32","DOI":"10.3390\/pharmaceutics9030032","article-title":"Revisiting the latency of uridine diphosphate-glucuronosyltransferases (UGTs)\u2014How does the endoplasmic reticulum membrane influence their function?","volume":"9","author":"Liu","year":"2017","journal-title":"Pharmaceutics"},{"issue":"2","key":"10.1016\/j.pharmthera.2024.108773_bb0400","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1007\/BF00178720","article-title":"Morphine-6-O-\u03b2-D-glucuronide but not morphine-3-O-\u03b2-D-glucuronide binds to \u03bc-, \u03b4- and \u03ba-specific opioid binding sites in cerebral membranes","volume":"354","author":"L\u00f6ser","year":"1996","journal-title":"Naunyn-Schmiedeberg\u2019s Archives of Pharmacology"},{"issue":"2","key":"10.1016\/j.pharmthera.2024.108773_bb0405","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics15020484","article-title":"Advances in oral drug delivery systems: Challenges and opportunities","volume":"15","author":"Lou","year":"2023","journal-title":"Pharmaceutics"},{"issue":"7","key":"10.1016\/j.pharmthera.2024.108773_bb0410","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1124\/dmd.117.075945","article-title":"Crypt organoid culture as an in vitro model in drug metabolism and cytotoxicity studies","volume":"45","author":"Lu","year":"2017","journal-title":"Drug Metabolism and Disposition"},{"key":"10.1016\/j.pharmthera.2024.108773_bb0415","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.jpba.2014.01.025","article-title":"Simultaneous determination of bilirubin and its glucuronides in liver microsomes and recombinant UGT1A1 enzyme incubation systems by HPLC method and its application to bilirubin glucuronidation studies","volume":"92","author":"Ma","year":"2014","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"key":"10.1016\/j.pharmthera.2024.108773_bb0420","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1097\/00008571-199708000-00001","article-title":"The UDP glycosyltransferase gene superfamily: Recommended nomenclature update based on evolutionary divergence","volume":"7","author":"Mackenzie","year":"1997","journal-title":"Pharmacogenetics"},{"issue":"10","key":"10.1016\/j.pharmthera.2024.108773_bb0425","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1097\/01.fpc.0000173483.13689.56","article-title":"Nomenclature update for the mammalian UDP glycosyltransferase (UGT) gene superfamily","volume":"15","author":"Mackenzie","year":"2005","journal-title":"Pharmacogenetics and Genomics"},{"issue":"8","key":"10.1016\/j.pharmthera.2024.108773_bb0430","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1080\/17425247.2018.1503249","article-title":"Targeting the intestinal lymphatic system: A versatile path for enhanced oral bioavailability of drugs","volume":"15","author":"Managuli","year":"2018","journal-title":"Expert Opinion on Drug Delivery"},{"issue":"2","key":"10.1016\/j.pharmthera.2024.108773_bb0435","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1002\/med.21533","article-title":"Lipidic prodrug approach for improved oral drug delivery and therapy","volume":"39","author":"Markovic","year":"2019","journal-title":"Medicinal Research Reviews"},{"issue":"5","key":"10.1016\/j.pharmthera.2024.108773_bb0440","article-title":"Interspecies comparison of the glucuronidation processes in the man, monkey, pig, dog and rat","volume":"29","author":"Matal","year":"2008","journal-title":"Neuroendocrinology Letters"},{"key":"10.1016\/j.pharmthera.2024.108773_bb0445","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.pharmthera.2016.01.009","article-title":"The role of glucuronidation in drug resistance","volume":"159","author":"Mazerska","year":"2016","journal-title":"Pharmacology & Therapeutics"},{"key":"10.1016\/j.pharmthera.2024.108773_bb0450","author":"Medicines Agency, E"},{"issue":"2","key":"10.1016\/j.pharmthera.2024.108773_bb0455","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1152\/physrev.00058.2017","article-title":"The UDP-glycosyltransferase (UGT) superfamily: New members, new functions, and novel paradigms","volume":"99","author":"Meech","year":"2019","journal-title":"Physiological Reviews"},{"key":"10.1016\/j.pharmthera.2024.108773_bb0460","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1111\/j.1440-1681.1997.tb02718.x","article-title":"Structure and function of uridine diphosphate glucuronosyltransferases","volume":"24","author":"Meech","year":"1997","journal-title":"Clinical and Experimental Pharmacology and Physiology"},{"issue":"6","key":"10.1016\/j.pharmthera.2024.108773_bb0465","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.ctrv.2008.03.002","article-title":"Combined action and regulation of phase II enzymes and multidrug resistance proteins in multidrug resistance in cancer","volume":"34","author":"Meijerman","year":"2008","journal-title":"Cancer Treatment Reviews"},{"issue":"2","key":"10.1016\/j.pharmthera.2024.108773_bb0470","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/0163-7258(88)90099-X","article-title":"Influence of food on the presystemic metabolism of drugs","volume":"38","author":"Melander","year":"1988","journal-title":"Pharmacology & Therapeutics"},{"key":"10.1016\/j.pharmthera.2024.108773_bb0475","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.mtchem.2018.09.001","article-title":"Rectal administration of nanosystems: From drug delivery to diagnostics","volume":"10","author":"Melo","year":"2018","journal-title":"Materials Today Chemistry"},{"issue":"1","key":"10.1016\/j.pharmthera.2024.108773_bb0480","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1124\/dmd.121.000644","article-title":"Intestinal UDP-glucuronosyltransferase 1A1 and protection against irinotecan-induced toxicity in a novel UDP-glucuronosyltransferase 1A1 tissue-specific humanized mouse model","volume":"50","author":"Mennillo","year":"2022","journal-title":"Drug Metabolism and Disposition"},{"key":"10.1016\/j.pharmthera.2024.108773_bb0485","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.bcp.2017.01.002","article-title":"Inhibition of human UDP-glucuronosyltransferase enzymes by lapatinib, pazopanib, regorafenib and sorafenib: Implications for hyperbilirubinemia","volume":"129","author":"Miners","year":"2017","journal-title":"Biochemical Pharmacology"},{"issue":"11","key":"10.1016\/j.pharmthera.2024.108773_bb0490","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1016\/j.bcp.2005.12.019","article-title":"In vitro\u2013in vivo correlation for drugs and other compounds eliminated by glucuronidation in humans: Pitfalls and promises","volume":"71","author":"Miners","year":"2006","journal-title":"Biochemical Pharmacology"},{"issue":"1","key":"10.1016\/j.pharmthera.2024.108773_bb0495","doi-asserted-by":"crossref","first-page":"196","DOI":"10.3109\/03602530903210716","article-title":"The prediction of drug-glucuronidation parameters in humans: UDP-glucuronosyltransferase enzyme-selective substrate and inhibitor probes for reaction phenotyping and in vitro-in vivo extrapolation of drug clearance and drug-drug interaction potential","volume":"42","author":"Miners","year":"2010","journal-title":"Drug Metabolism Reviews"},{"key":"10.1016\/j.pharmthera.2024.108773_bb0500","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2020.107689","article-title":"Evidence-based strategies for the characterisation of human drug and chemical glucuronidation in vitro and UDP-glucuronosyltransferase reaction phenotyping","volume":"218","author":"Miners","year":"2021","journal-title":"Pharmacology & Therapeutics"},{"issue":"2","key":"10.1016\/j.pharmthera.2024.108773_bb0505","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1111\/j.1530-0277.1989.tb00324.x","article-title":"Impaired hepatic elimination of Paranitrophenol and its metabolites in the rat following chronic ethanol pretreatment","volume":"13","author":"Mitchell","year":"1989","journal-title":"Alcoholism: Clinical and Experimental Research"},{"issue":"1","key":"10.1016\/j.pharmthera.2024.108773_bb0510","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1080\/10717544.2017.1334719","article-title":"Engineering of a novel optimized platform for sublingual delivery with novel characterization tools: In vitro evaluation and in vivo pharmacokinetics study in human","volume":"24","author":"Morsi","year":"2017","journal-title":"Drug Delivery"},{"issue":"7","key":"10.1016\/j.pharmthera.2024.108773_bb0515","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1124\/dmd.106.009621","article-title":"Human UDP-glucuronosyltransferase UGT1A8, glucuronidates dihydrotestosterone to a monoglucuronide and further to a structurally novel diglucuronide","volume":"34","author":"Murai","year":"2006","journal-title":"Drug Metabolism and Disposition"},{"issue":"8","key":"10.1016\/j.pharmthera.2024.108773_bb0520","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1124\/dmd.108.021428","article-title":"Expression of UGT1A and UGT2B mRNA in human Normal tissues and various cell lines","volume":"36","author":"Nakamura","year":"2008","journal-title":"Drug Metabolism and Disposition"},{"key":"10.1016\/j.pharmthera.2024.108773_bb0525","article-title":"Sublingual mucosa as a route for systemic drug delivery","volume":"3","author":"Narang","year":"2011","journal-title":"International Journal of Pharmacy and Pharmaceutical Sciences"},{"issue":"6","key":"10.1016\/j.pharmthera.2024.108773_bb0530","doi-asserted-by":"crossref","first-page":"592","DOI":"10.2133\/dmpk.DMPK-11-RG-034","article-title":"Prediction of the intestinal first-pass metabolism of CYP3A and UGT substrates in humans from in vitro data","volume":"26","author":"Nishimuta","year":"2011","journal-title":"Drug Metabolism and Pharmacokinetics"},{"issue":"1","key":"10.1016\/j.pharmthera.2024.108773_bb0535","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.dmpk.2014.12.001","article-title":"A comprehensive review of UDP-glucuronosyltransferase and esterases for drug development","volume":"30","author":"Oda","year":"2015","journal-title":"Drug Metabolism and Pharmacokinetics"},{"issue":"21","key":"10.1016\/j.pharmthera.2024.108773_bb0540","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ijms21218224","article-title":"Pharmaceutical excipients and drug metabolism: A Mini-review","volume":"21","author":"Patel","year":"2020","journal-title":"International Journal of Molecular Sciences"},{"key":"10.1016\/j.pharmthera.2024.108773_bb0545","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.jconrel.2014.09.031","article-title":"Targeting of gastrointestinal tract for amended delivery of protein\/peptide therapeutics: Strategies and industrial perspectives","volume":"196","author":"Pawar","year":"2014","journal-title":"Journal of Controlled Release"},{"key":"10.1016\/j.pharmthera.2024.108773_bb0550","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.jconrel.2014.08.004","article-title":"Pre-systemic metabolism of orally administered drugs and strategies to overcome it","volume":"192","author":"Pereira De Sousa","year":"2014","journal-title":"Journal of Controlled Release"},{"issue":"5","key":"10.1016\/j.pharmthera.2024.108773_bb0555","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/0011-393X(95)85078-3","article-title":"Oral bambuterol versus terbutaline in patients with asthma","volume":"56","author":"Persson","year":"1995","journal-title":"Current Therapeutic Research"},{"key":"10.1016\/j.pharmthera.2024.108773_bb0560","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2021.116388","article-title":"CYPlebrity: Machine learning models for the prediction of inhibitors of cytochrome P450 enzymes","volume":"46","author":"Plonka","year":"2021","journal-title":"Bioorganic & Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2024.108773_bb0565","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.toxrep.2020.12.019","article-title":"Species differences in phenobarbital-mediated UGT gene induction in rat and human liver microtissues","volume":"8","author":"Plummer","year":"2021","journal-title":"Toxicology Reports"},{"issue":"FEB","key":"10.1016\/j.pharmthera.2024.108773_bb0570","article-title":"Cancer chemoprevention and piperine: Molecular mechanisms and therapeutic opportunities","volume":"6","author":"Rather","year":"2018","journal-title":"Frontiers in Cell and Developmental Biology"},{"issue":"1\u20132","key":"10.1016\/j.pharmthera.2024.108773_bb0575","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ijpharm.2013.02.030","article-title":"Approaches for enhancing oral bioavailability of peptides and proteins","volume":"447","author":"Renukuntla","year":"2013","journal-title":"International Journal of Pharmaceutics"},{"issue":"1","key":"10.1016\/j.pharmthera.2024.108773_bb0580","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1124\/dmd.109.029546","article-title":"Contribution of the different UDP-glucuronosyltransferase (UGT) isoforms to buprenorphine and norbuprenorphine metabolism and relationship with the main UGT polymorphisms in a bank of human liver microsomes","volume":"38","author":"Rouguieg","year":"2010","journal-title":"Drug Metabolism and Disposition"},{"key":"10.1016\/j.pharmthera.2024.108773_bb0585","article-title":"Handbook of pharmaceutical excipients","author":"Rowe","year":"2009","journal-title":"Revue Des Nouvelles Technologies de l\u2019Information."},{"issue":"6","key":"10.1016\/j.pharmthera.2024.108773_bb0590","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.biocel.2013.02.019","article-title":"The UDP-glucuronosyltransferases: Their role in drug metabolism and detoxification","volume":"45","author":"Rowland","year":"2013","journal-title":"The International Journal of Biochemistry & Cell Biology"},{"issue":"7","key":"10.1016\/j.pharmthera.2024.108773_bb0595","doi-asserted-by":"crossref","first-page":"605","DOI":"10.3109\/00498254.2015.1101509","article-title":"Species and tissue differences in serotonin glucuronidation","volume":"46","author":"Sakakibara","year":"2016","journal-title":"Xenobiotica"},{"issue":"6","key":"10.1016\/j.pharmthera.2024.108773_bb0600","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1016\/j.drudis.2022.02.022","article-title":"How nano-engineered delivery systems can help marketed and repurposed drugs in Alzheimer\u2019s disease treatment?","volume":"27","author":"S\u00e9guy","year":"2022","journal-title":"Drug Discovery Today"},{"issue":"1\u20132","key":"10.1016\/j.pharmthera.2024.108773_bb0605","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.cccn.2005.02.023","article-title":"Glucuronidation in therapeutic drug monitoring","volume":"358","author":"Shipkova","year":"2005","journal-title":"Clinica Chimica Acta"},{"issue":"9","key":"10.1016\/j.pharmthera.2024.108773_bb0610","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1124\/dmd.108.021469","article-title":"Species differences in UDP-glucuronosyltransferase activities in mice and rats","volume":"36","author":"Shiratani","year":"2008","journal-title":"Drug Metabolism and Disposition"},{"key":"10.1016\/j.pharmthera.2024.108773_bb0615","series-title":"Buprenorphine treatment for opioid use disorder: An overview","author":"Shulman","year":"2019"},{"issue":"11","key":"10.1016\/j.pharmthera.2024.108773_bb0620","doi-asserted-by":"crossref","first-page":"934","DOI":"10.3109\/00498254.2011.593209","article-title":"In vitro interaction of a novel neutrophil growth factor with human liver microsomal cytochromes P450 and the contribution of UDP-glucuronosyltransferases to its metabolism","volume":"41","author":"\u0160iller","year":"2011","journal-title":"Xenobiotica"},{"issue":"1","key":"10.1016\/j.pharmthera.2024.108773_bb0625","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1124\/jpet.301.1.382","article-title":"In vitro analysis of human drug Glucuronidation and prediction of in vivo metabolic clearance","volume":"301","author":"Soars","year":"2002","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"issue":"7","key":"10.1016\/j.pharmthera.2024.108773_bb0630","doi-asserted-by":"crossref","first-page":"3546","DOI":"10.1021\/acs.jmedchem.0c01930","article-title":"Successful and unsuccessful prediction of human hepatic clearance for Lead optimization","volume":"64","author":"Sodhi","year":"2021","journal-title":"Journal of Medicinal Chemistry"},{"issue":"11","key":"10.1016\/j.pharmthera.2024.108773_bb0635","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1124\/dmd.109.029231","article-title":"UDP-glucuronosyltransferases in conjugation of 5\u03b1- and 5\u03b2-Androstane steroids","volume":"37","author":"Sten","year":"2009","journal-title":"Drug Metabolism and Disposition"},{"issue":"1","key":"10.1016\/j.pharmthera.2024.108773_bb0640","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.pharmthera.2013.09.002","article-title":"Relevance of UDP-glucuronosyltransferase polymorphisms for drug dosing: A quantitative systematic review","volume":"141","author":"Stingl","year":"2014","journal-title":"Pharmacology & Therapeutics"},{"key":"10.1016\/j.pharmthera.2024.108773_bb0645","doi-asserted-by":"crossref","DOI":"10.1016\/j.dmpk.2023.100811","article-title":"Relative expression versus activity factor (ref vs. raf) to estimate fractional contribution of individual UGT isoforms (FGLUC) in drug glucuronidation","volume":"55","author":"Subash","year":"2024","journal-title":"Drug Metabolism and Pharmacokinetics"},{"issue":"8","key":"10.1016\/j.pharmthera.2024.108773_bb0650","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1007\/s11095-024-03750-x","article-title":"Comparison of relative activity versus relative expression factors (RAF versus REF) in predicting Glucuronidation mediated drug clearance using recombinant UGTs","volume":"41","author":"Subash","year":"2024","journal-title":"Pharmaceutical Research"},{"issue":"3","key":"10.1016\/j.pharmthera.2024.108773_bb0655","doi-asserted-by":"crossref","first-page":"255","DOI":"10.2217\/nnm-2016-0331","article-title":"Nanocarriers protecting toward an intestinal pre-uptake metabolism","volume":"12","author":"Suchaoin","year":"2017","journal-title":"Nanomedicine"},{"key":"10.1016\/j.pharmthera.2024.108773_bb0660","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.fct.2017.11.009","article-title":"Species differences between rat and human in vitro metabolite profile, in vivo predicted clearance, CYP450 inhibition and CYP450 isoforms that metabolize benzanthrone: Implications in risk assessment","volume":"111","author":"Taneja","year":"2018","journal-title":"Food and Chemical Toxicology"},{"issue":"Suppl. 134","key":"10.1016\/j.pharmthera.2024.108773_bb0665","first-page":"93","article-title":"Elimination pathways of terbutaline","volume":"134","author":"Tegner","year":"1984","journal-title":"European Journal of Respiratory Diseases. Supplement"},{"issue":"3","key":"10.1016\/j.pharmthera.2024.108773_bb0670","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/epi.12109","article-title":"Antiepileptic drug treatment in pregnancy: Changes in drug disposition and their clinical implications","volume":"54","author":"Tomson","year":"2013","journal-title":"Epilepsia"},{"issue":"12","key":"10.1016\/j.pharmthera.2024.108773_bb0675","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1124\/dmd.107.016972","article-title":"In vitro Glucuronidation of thyroxine and triiodothyronine by liver microsomes and recombinant human UDP-glucuronosyltransferases","volume":"35","author":"Tong","year":"2007","journal-title":"Drug Metabolism and Disposition"},{"issue":"4","key":"10.1016\/j.pharmthera.2024.108773_bb9160","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/j.1365-2125.2009.03363.x","article-title":"Effects of UGT1A1*28 polymorphism on raloxifene pharmacokinetics and pharmacodynamics","volume":"67","author":"Trontelj","year":"2009","journal-title":"British Journal of Clinical Pharmacology"},{"key":"10.1016\/j.pharmthera.2024.108773_bb0680","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1146\/annurev.pharmtox.40.1.581","article-title":"Human UDP-glucuronosyltransferases: Metabolism, expression, and disease","volume":"40","author":"Tukey","year":"2000","journal-title":"Annual Review of Pharmacology and Toxicology"},{"issue":"6","key":"10.1016\/j.pharmthera.2024.108773_bb0685","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1194\/jlr.M300010-JLR200","article-title":"Glucuronidation of arachidonic and linoleic acid metabolites by human UDP-glucuronosyltransferases","volume":"44","author":"Turgeon","year":"2003","journal-title":"Journal of Lipid Research"},{"key":"10.1016\/j.pharmthera.2024.108773_bb0690","author":"US-FDA, Administration, D"},{"issue":"5","key":"10.1016\/j.pharmthera.2024.108773_bb0695","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1124\/dmd.111.043117","article-title":"Optimized assays for human UDP-glucuronosyltransferase (UGT) activities: Altered alamethicin concentration and utility to screen for UGT inhibitors","volume":"40","author":"Walsky","year":"2012","journal-title":"Drug Metabolism and Disposition"},{"issue":"1","key":"10.1016\/j.pharmthera.2024.108773_bb0700","doi-asserted-by":"crossref","first-page":"54522","DOI":"10.1371\/journal.pone.0054522","article-title":"Glucuronidation by UGT1A1 is the dominant pathway of the metabolic disposition of belinostat in liver cancer patients","volume":"8","author":"Wang","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2024.108773_bb0705","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ijpharm.2019.02.027","article-title":"Involvement of metabolism-permeability in enhancing the oral bioavailability of curcumin in excipient-free solid dispersions co-formed with piperine","volume":"561","author":"Wang","year":"2019","journal-title":"International Journal of Pharmaceutics"},{"issue":"11","key":"10.1016\/j.pharmthera.2024.108773_bb0710","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1124\/dmd.106.009910","article-title":"Disposition of flavonoids via enteric recycling: Structural effects and lack of correlations between in vitro and in situ metabolic properties","volume":"34","author":"Wang","year":"2006","journal-title":"Drug Metabolism and Disposition"},{"issue":"5","key":"10.1016\/j.pharmthera.2024.108773_bb0715","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2024.107278","article-title":"A novel system to determine activity of individual uridine 5\u2032-diphospho-glucuronosyltransferase (UGT) isoforms: Recombinant UGT-beads","volume":"300","author":"Wang","year":"2024","journal-title":"Journal of Biological Chemistry"},{"issue":"6","key":"10.1016\/j.pharmthera.2024.108773_bb0720","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1210\/en.2013-2013","article-title":"Human UGT1A4 and UGT1A3 conjugate 25-hydroxyvitamin D3: Metabolite structure, kinetics, inducibility, and interindividual variability","volume":"155","author":"Wang","year":"2014","journal-title":"Endocrinology"},{"issue":"21","key":"10.1016\/j.pharmthera.2024.108773_bb0725","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1056\/NEJMra032424","article-title":"Drug metabolism and variability among patients in drug response","volume":"352","author":"Wilkinson","year":"2005","journal-title":"New England Journal of Medicine"},{"issue":"11","key":"10.1016\/j.pharmthera.2024.108773_bb0730","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1124\/dmd.104.000794","article-title":"Drug-drug interactions for UDP-glucuronosyltransferase substrates: A pharmacokinetic explanation for typically observed low exposure (AUCI\/AUC) ratios","volume":"32","author":"Williams","year":"2004","journal-title":"Drug Metabolism and Disposition"},{"issue":"3","key":"10.1016\/j.pharmthera.2024.108773_bb0735","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/BF03190479","article-title":"Metabolic fate of the antipsychotic agent, mazapertine, in man - API-MS and MS\/MS identification of urinary metabolites","volume":"32","author":"Wu","year":"2007","journal-title":"European Journal of Drug Metabolism and Pharmacokinetics"},{"key":"10.1016\/j.pharmthera.2024.108773_bb0740","doi-asserted-by":"crossref","DOI":"10.1016\/j.colsurfb.2020.111069","article-title":"Enhancing in vivo oral bioavailability of cajaninstilbene acid using UDP-glucuronosyl transferase inhibitory excipient containing self-microemulsion","volume":"193","author":"Yang","year":"2020","journal-title":"Colloids and Surfaces B: Biointerfaces"},{"key":"10.1016\/j.pharmthera.2024.108773_bb0745","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.ejps.2017.12.026","article-title":"Improving oral bioavailability of resveratrol by a UDP-glucuronosyltransferase inhibitory excipient-based self-microemulsion","volume":"114","author":"Yang","year":"2018","journal-title":"European Journal of Pharmaceutical Sciences"},{"issue":"2","key":"10.1016\/j.pharmthera.2024.108773_bb0750","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1080\/03602532.2017.1293682","article-title":"Glucuronidation: Driving factors and their impact on glucuronide disposition","volume":"49","author":"Yang","year":"2017","journal-title":"Drug Metabolism Reviews"},{"key":"10.1016\/j.pharmthera.2024.108773_bb0755","doi-asserted-by":"crossref","first-page":"6503","DOI":"10.2147\/IJN.S259993","article-title":"A non-lipolysis nanoemulsion improved oral bioavailability by reducing the first-pass metabolism of raloxifene, and related absorption mechanisms being studied","volume":"15","author":"Ye","year":"2020","journal-title":"International Journal of Nanomedicine"},{"issue":"6","key":"10.1016\/j.pharmthera.2024.108773_bb0760","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1111\/j.1365-2125.1989.tb03555.x","article-title":"Interindividual and interethnic differences in the demethylation and glucuronidation of codeine","volume":"28","author":"Yue","year":"1989","journal-title":"British Journal of Clinical Pharmacology"},{"issue":"32","key":"10.1016\/j.pharmthera.2024.108773_bb0765","doi-asserted-by":"crossref","first-page":"19815","DOI":"10.1039\/C6RA27096D","article-title":"Development and characterization of promising Cremophor EL-stabilized o\/w nanoemulsions containing short-chain alcohols as a cosurfactant","volume":"7","author":"Zeng","year":"2017","journal-title":"RSC Advances"},{"issue":"10","key":"10.1016\/j.pharmthera.2024.108773_bb0770","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2023.103728","article-title":"Comparison and summary of in silico prediction tools for CYP450-mediated drug metabolism","volume":"28","author":"Zhai","year":"2023","journal-title":"Drug Discovery Today"},{"issue":"6","key":"10.1016\/j.pharmthera.2024.108773_bb0775","doi-asserted-by":"crossref","first-page":"6832","DOI":"10.3390\/molecules17066832","article-title":"Strong inhibition of celastrol towards UDP-glucuronosyl transferase (UGT) 1A6 and 2B7 indicating potential risk of UGT-based herb-drug interaction","volume":"17","author":"Zhang","year":"2012","journal-title":"Molecules"},{"issue":"8","key":"10.1016\/j.pharmthera.2024.108773_bb0780","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.2174\/138920012802850100","article-title":"Nano-based drug delivery system enhances the Oral absorption of lipophilic drugs with extensive Presystemic metabolism","volume":"13","author":"Zhang","year":"2012","journal-title":"Current Drug Metabolism"},{"issue":"10","key":"10.1016\/j.pharmthera.2024.108773_bb0785","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1093\/bioinformatics\/btp140","article-title":"Site of metabolism prediction for six biotransformations mediated by cytochromes P450","volume":"25","author":"Zheng","year":"2009","journal-title":"Bioinformatics"},{"issue":"4","key":"10.1016\/j.pharmthera.2024.108773_bb0790","doi-asserted-by":"crossref","first-page":"263","DOI":"10.3390\/pharmaceutics10040263","article-title":"A comprehensive map of FDA-approved pharmaceutical products","volume":"10","author":"Zhong","year":"2018","journal-title":"Pharmaceutics"},{"issue":"4","key":"10.1016\/j.pharmthera.2024.108773_bb0795","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1021\/mp5005838","article-title":"Involvement of the inhibition of intestinal glucuronidation in enhancing the oral bioavailability of resveratrol by labrasol containing nanoemulsions","volume":"12","author":"Zhou","year":"2015","journal-title":"Molecular Pharmaceutics"},{"key":"10.1016\/j.pharmthera.2024.108773_bb0800","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.ijbiomac.2021.03.073","article-title":"A broad-spectrum substrate for the human UDP-glucuronosyltransferases and its use for investigating glucuronidation inhibitors","volume":"180","author":"Zhou","year":"2021","journal-title":"International Journal of Biological Macromolecules"}],"container-title":["Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725824001931?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725824001931?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T20:02:35Z","timestamp":1736452955000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725824001931"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":161,"alternative-id":["S0163725824001931"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2024.108773","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Glucuronidation of orally administered drugs and the value of nanocarriers in strategies for its overcome","name":"articletitle","label":"Article Title"},{"value":"Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmthera.2024.108773","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"108773"}}